U.S. markets open in 1 hour 19 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
172.95+1.69 (+0.99%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close171.26
Open171.40
Bid169.73 x 800
Ask177.02 x 4000
Day's Range168.55 - 173.12
52 Week Range119.29 - 178.41
Volume676,516
Avg. Volume535,106
Market Cap20.329B
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-7.55
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est174.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Alnylam to Host Eighth Annual "RNAi Roundtable" Webcast Series
    Business Wire

    Alnylam to Host Eighth Annual "RNAi Roundtable" Webcast Series

    CAMBRIDGE, Mass., June 23, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8th annual series of "RNAi Roundtable" webinars over the coming weeks. The series will offer a range of presentations from Alnylam scientists and program leaders who will review recent progress in many of the Company’s pipeline programs and platform innovations, as well as medical thought leaders who will provide their perspectives on cli

  • 3 Biotech Stocks With Big Catalysts in June
    Motley Fool

    3 Biotech Stocks With Big Catalysts in June

    Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

  • Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
    Business Wire

    Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from a Phase 3b open-label study conducted to evaluate the safety, efficacy and pharmacokinetics (PK) of patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy progression after receiving an orthotopic liver transplant (OLT). In patients treated with patisiran, the median reduction in serum TTR levels compared to baseline was 91 percent, measured as an aver